What question did this study set out to answer?

To evaluate the effects of the antihypertensive drug moxonidine on the plasma aldosterone/renin ratio used to screen for primary aldosteronism.

March 16, 2017The Journal of Clinical Endocrinology & MetabolismOpen Access

Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers

View Full Paper

Ask AI

Bookmark

Why the study?

Does moxonidine alter the aldosterone/renin ratio in normotensive, nonmedicated male volunteers?

Population

Normotensive, nonmedicated male volunteers (n=20)

Comparison

Moxonidine 0.2 mg/d for 1 week, followed by 0.4… vs Baseline (pre-intervention)

Design

Cohort

Follow-up

6 weeks

Authors

AAAshraf AhmedKing Fahd University of Petroleum and Minerals RGRichard D. GordonGeneral Motors (United States)GWGregory J. WardSmart Solution (Norway)

Discussion

Member takes

Implication

Moxonidine may be continued during ARR screening without confounding; first data in normotensives leave open validation in hypertensive patients.

Key Points

To evaluate the effects of the antihypertensive drug moxonidine on the plasma aldosterone/renin ratio used to screen for primary aldosteronism.
Enrolled 20 normotensive, nonmedicated male volunteers.
Administered moxonidine at 0.2 mg/day for 1 week, followed by 0.4 mg/day for an additional 5 weeks.
Measured seated midmorning plasma aldosterone (via HPLC-MS/MS), direct renin concentration (DRC), plasma renin activity (PRA), electrolytes, and urinary parameters at baseline, week 1, and week 6.
Systolic and diastolic blood pressure decreased significantly, but plasma aldosterone, DRC, and PRA levels showed no statistically significant changes at 1 or 6 weeks compared to baseline.
Median ARR using DRC was 8.0 (range, 4.4–14.4) at baseline, 8.8 (4.2–15.9) at week 1, and 7.7 (4.3–22.4) at week 6, reflecting no significant change.
Median ARR using PRA was 73 (range, 36–218) at baseline, 73 (32–194) at week 1, and 84 (32–192) at week 6, with no significant alterations in any urinary measurements.

Structured PICO

Does moxonidine alter the aldosterone/renin ratio in normotensive, nonmedicated male volunteers?

Population

Normotensive, nonmedicated male volunteers (n=20)

Intervention

Moxonidine 0.2 mg/d for 1 week, followed by 0.4 mg/d for a further 5 weeks

Comparator

Baseline (pre-intervention)

Outcome

Aldosterone/renin ratio (ARR) using direct renin concentration (DRC) or plasma renin activity (PRA)surrogate

Moxonidine does not significantly alter the aldosterone/renin ratio, suggesting it may be a suitable antihypertensive option to maintain blood pressure control when screening for primary aldosteronism.

Cite This Study

Ahmed et al. (2017) studied this question.

synapsesocial.com/papers/6a70f3926ceb2bbd16e00958 https://doi.org/10.1210/jc.2016-3821

View Full Paper

Ask AI

Bookmark

Implication

Moxonidine may be continued during ARR screening without confounding; first data in normotensives leave open validation in hypertensive patients.

Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider